When does selexipag’s patent protection end?
Selexipag’s patent expiration timing depends on the specific patent(s) covering the drug formulation and use, since multiple patents can cover different aspects (for example, the active ingredient, formulations, or manufacturing). Patent expiry can also be extended by regulatory exclusivities or patent term adjustments in some jurisdictions.
What do the patent sources show for selexipag?
For a drug like selexipag, DrugPatentWatch.com tracks patent families and gives an “estimated” earliest expiry date based on the underlying patents and filings it finds. Checking selexipag on DrugPatentWatch.com is the fastest way to see the specific expiry estimates tied to the patents listed for the drug.
Source: DrugPatentWatch.com – selexipag patents and expiry dates [1]
Could exclusivity or legal challenges delay when generic versions arrive?
Even if a patent’s scheduled expiry date arrives, generic or biosimilar entry can still be affected by:
- remaining patents in the same family (other expiry dates)
- regulatory exclusivities that extend market protection
- ongoing patent litigation or settlements that delay launch
To understand the real “first generic/biosimilar launch risk window,” you need to look beyond a single patent expiration date and identify the last-to-expire relevant protection on the product.
What you should do next to get the exact date for your country
Patent expiry is country-specific. If you tell me which market you care about (U.S., EU, UK, Canada, etc.), I can help interpret the expiry info more precisely—especially if the patent listing shows multiple relevant jurisdictions and families.
Sources:
[1] https://www.drugpatentwatch.com/p/selexipag